The Role of TCF7L2 in Type 2 Diabetes

Laura Del Bosque-Plata, Eduardo Martínez-Martínez, Miguel Ángel Espinoza-Camacho, Claudia Gragnoli

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations

Abstract

TCF7L2 is the most potent locus for type 2 diabetes (T2D) risk and the first locus to have been robustly reported by genomic linkage studies. TCF7L2 is a transcription factor that forms a basic part of the Wnt signaling pathway. This gene has highly conserved sequence regions that correspond to functional domains. The association of TCF7L2 with T2D is one of the most powerful genetically discovered in studies of complex diseases, as it has been consistently replicated in multiple populations with diverse genetic origins. The mechanisms over which TCF7L2 exerts its effect on T2D are still not well understood. In this article, we describe the main molecular mechanisms of how TCF7L2 is related to T2D. TCF7L2 variants associated with T2D risk exert an influence on the initial therapeutic success of the hypoglycemic oral agent sulfonylurea. Thus, it is important to know whether there are other TCF7L2 variants associated with T2D that can influence treatment with oral hypoglycemic agents. Resequencing of the TCF7L2 gene in diverse ethnic groups is required to reveal common and rare variations and their role in different pathologies and in adverse reactions to drugs. Identification of TCF7L2-susceptibility disease variants will permit, at a given moment, offering of therapies to patients according to their genotype.

Original languageEnglish (US)
Pages (from-to)1220-1228
Number of pages9
JournalDiabetes
Volume70
Issue number6
DOIs
StatePublished - Jun 1 2021

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Fingerprint

Dive into the research topics of 'The Role of TCF7L2 in Type 2 Diabetes'. Together they form a unique fingerprint.

Cite this